Drugs modifying nitric oxide metabolism affect plasma cholesterol levels, coagulation parameters, blood pressure values and the appearance of plasma myocardial necrosis markers in rabbits: Opposite effects of L-NAME and nitroglycerine

Cardiovascular Drugs and Therapy

Volumn 17, Issue 1, 2003, Pages 15-23

  Pinelli, Arnaldo ^a   Trivulzio, Silvio ^a   Tomasoni, Livio ^a   Bertolini, Boris ^a   Brenna, Sergio ^b   Bonacina, Edgardo ^b   Accinni, Roberto ^b  

^a Chemotherapy and Medical Toxicology ^*  (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Cardiac necrosis markers; Fibrinogen; HDL cholesterol; Mean arterial pressure (MAP); N nitro L arginine methyl ester (L NAME); Nitroglycerine; Partial thromboplastin time (PTT); Plasma nitric oxide (NO); Prothrombin time (PT); Total cholesterol

Indexed keywords

BIOLOGICAL MARKER; CREATINE KINASE; FIBRINOGEN; GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE INHIBITOR; TROPONIN I;

ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY RISK; DRUG EFFECT; FIBRINOGEN BLOOD LEVEL; HEART MUSCLE NECROSIS; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RABBIT;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CHOLESTEROL; CHOLESTEROL, HDL; MALE; MYOCARDIUM; NECROSIS; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITROGLYCERIN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RABBITS; VASODILATOR AGENTS;

EID: 0042347820     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024299523852     Document Type: Article

References (53)

1. Radomski MW, Moncada S. Regulation of vascular homeostasis by nitric oxide. Thrombosis and Haemostasis 1993;70:36-41.
2. Moncada S. The 1991 ULF von Euler lecture. The L-arginine: Nitric oxide pathway. Acta Physiol Scandinavica 1992;145:201-227.
3. Kelm M, Schrader J. Control of coronary vascular tone by nitric oxide. Circulation Res 1990;66:1561-1575.
4. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994;24:1468-1474.
5. Moreno Jr M, Nathan LP, Metze K, et al. Non-specific inhibitors of nitric oxide synthase cause myocardial necrosis in the rats. Clin Exp Pharmacol & Physiol 1997;24:349-352.
6. Ono Y, Ono H, Matsuoka H, Fujimori T, Frohlich ED. Apoptosis, coronary arterial remodeling and myocardial infarction after nitric oxide inhibition in SHR. Hypertension 1999;34:609-616.
7. Radomski MW, Palmer RM, Moncada S. An L-arginine: Nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990;87:5193-5197.
8. Dambisya YM, Lee TL. A thromboelastograhy study on the in vitro effects of L-arginine and L-NG-nitroarginine methyl ester on human whole blood coagulation and fibrinolysis. Blood Coagulation & Fibrinolysis 1996;7:678-683.
9. ωnitroarginine, elevates serum triglyceride and cholesterol and lowers hepatic fatty acid oxidation. J Nutr 1996;126:2563-2567.
10. Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production [1] accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arteriosclerosis & Thrombosis 1994;14:753-759.
11. 2 does not contribute to impaired endothelium-dependent relaxation. Arteriosclerosis & Thrombosis 1994;14:746-752.
12. Moncada S, Higgs A. The L-arginine nitric oxide pathway. New Engl J Med 1993;329:2002-2012.
13. Rang HP, Dale MM, Ritter JM. Pharmacology, IV Edition. London: Churchill Livingston, 1999.
14. Pasquinelli F. Diagnostica e tecniche di laboratorio. Milano: Rosini, 1997.
15. Marzinzig M, Nussler AK, Stadler J, et al. Improved methods to measure end products of nitric oxide in biological fluids: Nitrite, nitrate and s-nitrosothiols. Nitric Oxide 1997;1:177-189.
16. O'Brien PJ, Landt Y, Ladenson JH. Differential reactivity of cardiac and skeletal muscle from various species in a cardiac troponin I immunoassay. Clin Chem 1997;43:2333-2338.
17. Grand RJ, Wilkinson JM. The aminoacid sequence of rabbit cardiac troponin I. Biochem J 1976;159:633-641.
18. Vallins WJ, Brand NJ, Dabhade N, Buttler-Browne G, Yacoub MH. Molecular cloning of human cardiac Troponin I using polimerase chain reaction. FEBS Letters 1990;270:57-61.
19. Malouf NN, McMahon D, Oakeley AE, Anderson PA. A cardiac troponin T epitope conserved across phyla. J Biol Chem 1992;267:9269-9274.
20. Bodor GS, Porter S, Landt Y, Ladenson JH. The development of monoclonal antibodies and an assay for cardiac troponin-I with preliminary results in suspected myocardial infarction. Clin Chem 1992;11:2203-2214.
21. AFIP. Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology, 3rd Edition. New York: McGraw-Hill Book Company, 1968.
22. Armitage P. In Statistica Medica, X Edizione. Milano: Feltrinelli, 1991.
23. Senna SM, Moraes RB, Bravo MF, et al. Effects of prostaglandins and nitric oxide on rat macrophage lipid metabolism in culture: Implications for arterial wall-leukocyte interplay in atherosclerosis. Biochem & Mol Biol Int 1998;46:1007-1018.
24. Khedara A, Goto T, Kayashita J, Kato N. Hypercholesterolemic effect in rats of a dietary addition of the nitric oxide synthase inhibitor, L-N omega nitroarginine, by less synthesis of bile acids. Bioscience, Biotechnology & Biochemistry 1998;62:773-777.
25. Scalia R, Appel JZ 3rd, Lefer AM. Leukocyte-endothelium interaction during the early stages of hypercholesterolemia in the rabbit: Role of P-Selectin, ICAM-1, and VCAM-1. Arteriosclerosis, Thrombosis & Vascular Biology 1998;18: 1093-1100.
26. Kuvin JT, Ramet ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: Enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 2002;144:165-172.
27. Lippe IT, Sametz W, Sabin K, Holzer P. Inhibitory role of capsaicin-sensitive afferent neurons and nitric oxide in hemostasis. Am J Physiol 1993;265:H1864-H1868.
28. Catani MV, Bernassola F, Rossi A, Melino G. Inhibition of clotting factor XIII activity by nitric oxide. Biochem Biophys Res Comm 1998;249:275-278.
29. Kawabata A. Evidence that endogenous nitric oxide modulates plasma fibrinogen levels in the rat. Br J Pharmacol 1996;117:236-237.
30. Irokawa M, Nishinaga M, Ikeda U, et al. Endothelial-derived nitric oxide preserves anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. Atherosclerosis 1997;135:9-17.
31. Cella G, Sbarai A, Mazzaro G, et al. Plasma markers of endothelial dysfunction in chronic obstructive pulmonary disease. Clinical & Applied Thrombosis/Hemostasis 2001;7:205-208.
32. Moriguchi S, Ohzuru N, Koga N, et al. Central administration of a nitric oxide synthase inhibitor causes pressor responses via the sympathetic nervous system and the reninangiotensin system in Wistar rats. Neuroscience Letters 1998;245:109-112.
33. Kasuya A, Satoh S, Yoshida M, Hisa H, Suzuki-Kusaba M, Satoh S. Inhibitory effect of nitric oxide on the renin-angiotensin system in Dahl salt-sensitive rats. Clinical & Experimental Pharmacology & Physiology 1999;26:914-919.
34. Mathew V, Carman CR, Miller VM, et al. Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. Circulation 1997;96:1930-1936.
35. Buxton IL, Cheek DJ, Eckman D, Westfall DP, Sanders KM, Keef KD. NG-nitro L-arginine methyl ester and other alkyl esters of arginine are muscarinic receptor antagonists. Circulation Res 1993;72:387-395.
36. Cohen RI, Chen L, Scharf SM. The effects of high dose NG-nitro-L-arginine-methyl ester on myocardial blood flow and left ventricular function in dogs. J Critical Care 1996;11:206-213.
37. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60-68.
38. Nagata M, Sedgwick JB, Bates ME, Kita H, Busse WW. Eosinophil adhesion to vascular cell adhesion molecule-1 activates superoxide anion generation. J Immunol 1995;155:2194-2202.
39. Nagata M, Sedgwick JB, Busse WW. Differential effects of granulocyte-macrophage colony-stimulating factor on eosinophil and neutrophil superoxide anion generation. J Immunol 1995;155:4948-4954.
40. Lefer AM, Ma XL. Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery endothelium. Arteriosclerosis & Thrombosis 1993;13:771-776.
41. Boger RH, Bode-Boger SM, Kienke S, Stan AC, Nafe R, Frolich JC. Dietary L-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits. Atherosclerosis 1998;136:67-77.
42. Osterud B, Elvevoll EO, Brox J, et al. Haemostatic parameters related to lipids and adhesion molecules. Blood Coagulation & Fibrinolysis 1999;10:465-470.
43. Lindahl B, Andren B, Ohlsson J, Venge P, Wallentin L. Non-invasive risk stratification in unstable coronary artery disease: Exercise test and biochemical markers. FRISC study group. Am J Cardiol 1997;80:40E-44E.
44. Topol E. Patient stratification and its predictive value for cardiac events. Eur Heart J Suppl 1998;19:K5-K7.
45. Hamm CW. Risk stratifying acute coronary syndromes: Gradient of risk and benefit. Am Heart J 1999;138:S6-S11.
46. Bertinchant JP, Robert E, Polge A, et al. Comparison of the diagnostic value of cardiac troponin I and T determination for detecting early myocardial damage and the relationship with histological findings after isoprenaline-induced cardiac injury in rats. Clin Chim Acta 2000;298:13-28.
47. Bertsch T, Bleuel H, Deschl U, Rebel W. A new sensitive cardiac troponin T rapid test (TROPT) for the detection of experimental acute myocardial damage in rats. Exp Toxicol Pathol 1999;51:565-569.
48. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999;33:234-241.
49. Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arteriosclerosis Thrombosis & Vascular Biology 1999;19:2894-2900.
50. Tannous M, Cheung R, Vignini A, Mutus B. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thrombosis & Haemostasis 1999;82:1390-1394.
51. Di Napoli P, Antonio Taccardi A, Grilli A, et al. Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: An ex vivo study in isolated working rat hearts. Cardiovascular Res 2001;51:283-293.
52. Ni W, Egashira K, Kataoka C, et al. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circulation Res 2001;89:415-421.
53. Kayanoki Y, Kawata S, Yamasaki E, et al. Reduced nitric oxide production by L-arginine deficiency in lysinuric protein intolerance exacerbates intravascular coagulation. Metabolism: Clinical & Experimental 1999;48:1136-1140.